Marc Sutton

Articles edited by Marc Sutton

• Huntington’s Disease Therapeutics Conference 2026 – Day 3
• Huntington’s Disease Therapeutics Conference 2026 – Day 2
• Huntington’s Disease Therapeutics Conference 2026 – Day 1
• The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
• Worms to the Rescue: Separating the Good, the Bad, and the Clumpy Huntingtin
• Folding A Shirt With 12-Foot Arms: Understanding Protein Folding in Huntington’s Disease
• The First Domino Falls: AMT-130 Gene Therapy Slows Huntington’s in Landmark Trial
• Excitement and Anticipation as PTC’s Huntington’s Disease Drug Clears a Major Hurdle to Sprint Home
• Do Antidepressants Affect Cognitive Decline? There's More To The Story For Huntington's Disease
• Huntington’s Disease Heroes: A Gratitude Day Feature on Factor-H
• Huntington's Disease Therapeutics Conference 2025 – Day 3
• Huntington's Disease Therapeutics Conference 2025 – Day 2
• Spotting HD Early: The Clues Hidden in Young Brains
• Moving into the Fast Lane: uniQure and the FDA Are on the Same Track for Accelerated Approval
• Self-determination on the HD journey: the role of Advanced Care Planning
• Hope vs. hype: seeking truth in recent Prilenia headlines
• Hereditary Disease Foundation (HDF) conference 2024 – Day 4
• Hereditary Disease Foundation (HDF) conference 2024 – Day 3
• Hereditary Disease Foundation (HDF) conference 2024 – Day 2
• A new era for HDBuzz
• Understanding expansions at the single cell level
• Huntington's Disease Therapeutics Conference 2024 – Day 3
• Huntington's Disease Therapeutics Conference 2024 – Day 2
• Huntington's Disease Therapeutics Conference 2024 – Day 1
• Putting it in print: GENERATION HD1 study results published
• Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD
• Uncovering the dark side of DNA repair to design HD treatments
• Making babies: having a family, the HD way

Articles written by Marc Sutton

• Huntington’s Disease Therapeutics Conference 2026 – Day 3
• Huntington’s Disease Therapeutics Conference 2026 – Day 2
• Huntington’s Disease Therapeutics Conference 2026 – Day 1
• The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
• A tug-of-war at the DNA: how Huntington’s repeats grow and shrink
• A Map Through Time: Tracking Huntington’s Disease From Birth in the Brain
• Huntington’s Disease Clinical Research Congress 2025 – Day 3
• Huntington’s Disease Clinical Research Congress 2025 – Day 2
• Huntington’s Disease Clinical Research Congress 2025 – Day 1
• Full Steam Ahead: uniQure’s On Track With Hope for Accelerated Approval of Huntington’s Disease Drug
• Roche provides an update on tominersen: What’s next for this huntingtin-lowering drug?
• Huntington’s Disease Heroes: A Gratitude Day Feature on Factor-H
• Huntington's Disease Therapeutics Conference 2025 – Day 3
• Huntington's Disease Therapeutics Conference 2025 – Day 2
• Huntington's Disease Therapeutics Conference 2025 – Day 1
• Moving into the Fast Lane: uniQure and the FDA Are on the Same Track for Accelerated Approval
• Huntington Study Group (HSG) Conference 2024 – Day 3
• Huntington Study Group (HSG) Conference 2024 – Day 2
• Huntington Study Group (HSG) Conference 2024 – Day 1
• Hereditary Disease Foundation (HDF) conference 2024 – Day 4
• Hereditary Disease Foundation (HDF) conference 2024 – Day 3
• Hereditary Disease Foundation (HDF) conference 2024 – Day 2
• Hereditary Disease Foundation (HDF) conference 2024 – Day 1
• A new era for HDBuzz
• Huntington's Disease Therapeutics Conference 2024 – Day 3
• Huntington's Disease Therapeutics Conference 2024 – Day 2
• Huntington's Disease Therapeutics Conference 2024 – Day 1
• Putting it in print: GENERATION HD1 study results published
• Drug to treat movement symptoms of HD approved by FDA
• Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials
• Huntington’s disease therapeutics conference 2023 – Day 3
• Huntington’s disease therapeutics conference 2023 – Day 2
• Huntington’s disease therapeutics conference 2023 – Day 1
• Hunting for balance: how the huntingtin protein compensates in HD
• Update on the PTC Therapeutics PIVOT-HD Trial
• Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
• Hereditary Disease Foundation (HDF) conference 2022 – Day 4
• Hereditary Disease Foundation (HDF) conference 2022 – Day 3
• Hereditary Disease Foundation (HDF) conference 2022 – Day 2
• Hereditary Disease Foundation (HDF) conference 2022 – Day 1
• Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
• Updates from uniQure about their gene therapy for Huntington's disease
• Revisiting vitamin therapy for HD
• Huntington’s disease therapeutics conference 2022 – Day 3
• Huntington’s disease therapeutics conference 2022 – Day 2
• Huntington’s disease therapeutics conference 2022 – Day 1
• Oral drug may change the story for huntingtin lowering
• Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
• Real talk: Q&A with Roche about GENERATION-HD1
• Unpacking recent gene therapy press
• Huntington's disease therapeutics conference 2021 – Day 3
• Huntington's disease therapeutics conference 2021 – Day 2
• Huntington’s disease therapeutics conference 2021 – Day 1
• Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
• Sad News from Roche and Ionis – ASO Trial Halted Early
• Vaccines and HD
• Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2
• When genes are unstable: targeting somatic instability in HD
• Fountain of youth: HTT protein repairs neurons by maintaining youthful state
• What does COVID-19 mean for Huntington’s disease families and HD research?
• Huntington’s disease therapeutics conference 2020 – Day 3
• Huntington’s disease therapeutics conference 2020 – Day 2
• Huntington’s disease therapeutics conference 2020 – Day 1
• Huntington's disease therapeutics conference 2019 – Day 3
• Huntington's disease therapeutics conference 2019 – Day 2
• HDBuzz primer: Clinical trial designs and phases
• Start here!
• Making babies: having a family, the HD way

Articles translated by Marc Sutton

简体中文

• UniQure 收到 FDA 关于 AMT-130 的会议纪要，社区支持依然强劲

Français

• Le premier domino tombe : La thérapie génique AMT-130 ralentit la maladie de Huntington lors d’un essai historique

Nederlands

• 10 Gouden Regels voor het Navigeren door Onderzoeksnieuws over de ziekte van Huntington
• Wakker worden: Slaap wordt beïnvloed voordat symptomen van de ziekte van Huntington verschijnen
• Terugblik op 2024
• Bètablokkers geassocieerd met vertraagde aanvang en verminderde progressie van de ziekte van Huntington
• Kunnen spierproblemen helpen bij het verklaren van bewegingen bij de ziekte van Huntington?
• Genonderdrukkend medicijn veilig bij ALS-patiënten… op naar Huntington-trials

Português

• Prémio HDBuzz 2024: Competências Sociais – A Joia Escondida na Melhoria da Qualidade de Vida das Pessoas com Doença de Huntington?
• Um novo mapa para seguir a progressão da doença de Huntington
• Fazer bebés: ter uma família, à maneira da DH

Deutsch

• Ein fehlerhafter Filter? Blutgefäßveränderungen bei der Huntington-Krankheit
• Impfungen und die Huntington-Krankheit
• Huntington's Disease Therapeutics Conference 2019 – Tag 1
• Die Vorteile der Migration, hervorgehoben bei der Huntington-Krankheit
• Huntingtin greift zum Hammer: DNA-Reparatur bei HD
• Leider hat die PRIDE-HD-Studie NICHT gezeigt, dass Pridopidin das Fortschreiten der Huntington-Krankheit verlangsamt.
• Huntingtin macht einen Ausflug: schädliche Proteine verbreiten sich in Hirnzellen
• Gemeinsam Bäume pflanzen: Die Jahrestagung 2016 der Huntington’s Disease Society of America
• Deutetrabenazin für Huntington: positive Studienergebnisse aber die FDA sagt nein? Nicht unbedingt…

Español

• Revisión de la terapia vitamínica para la EH

Italiano

• La strada si illumina: Un nuovo biomarcatore per la Malattia di Huntington
• Una nuova tecnica è destinata a rivoluzionare i test genetici per la malattia di Huntington?